Evropská unie - estonština - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - leflunomiid - arthritis, rheumatoid; arthritis, psoriatic - immunosupressandid - leflunomiidi on näidustatud ravi täiskasvanud patsientidel:aktiivse reumatoidartriidi kui "haigust moduleeriva reumavastased uimasti" (dmard);aktiivse psoriaatilise artriidi. hiljutine või samaaegne ravi hepatotoxic või haematotoxic dmards e. metotreksaat) võib suurendada tõsiste kõrvaltoimete esinemise riski; seetõttu tuleb leflunomiidiravi alustamist nende kasu / riski aspektide osas hoolikalt kaaluda. lisaks sellele üleminek leflunomiidi teise dmard ilma pärast washout menetluse võib suureneda ka risk tõsiste kõrvaltoimete isegi pikka aega pärast lülitus.

Evropská unie - estonština - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriaas - immunosupressandid - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Evropská unie - estonština - EMA (European Medicines Agency)

bpl bioproducts laboratory gmbh - inimeste koagulatsiooni faktor x - faktori x puudus - vitamin k and other hemostatics, antihemorrhagics, coagulation factor x - coagadex on näidustatud verejooksude episoodide raviks ja profülaktikaks ning perioperatiivseks raviks päriliku faktori x puudulikkusega patsientidel. coagadex on märgitud igas vanuses.

Evropská unie - estonština - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - leflunomiid - artriit, reumatoidartriit - selektiivsed immunosupressandid - leflunomiidi on näidustatud ravi täiskasvanud patsientidel:aktiivse reumatoidartriidi kui "haigust moduleeriva reumavastased uimasti" (dmard). hiljutine või samaaegne ravi hepatotoxic või haematotoxic dmards e. metotreksaat) võib põhjustada suurenenud risk raskete kõrvaltoimete, seega algatamise leflunomiidi ravi on hoolikalt tuleb kaaluda seoses nimetatud kasu / riski aspekte. lisaks sellele üleminek leflunomiidi teise dmard ilma pärast washout menetluse võib suureneda ka risk tõsiste kõrvaltoimete isegi pikka aega pärast lülitus.

Evropská unie - estonština - EMA (European Medicines Agency)

amgen europe bv - apremilast - arthritis, psoriatic; psoriasis - immunosupressandid - psoriaatilise arthritisotezla, üksi või koos haigust moduleeriva reumavastased ravimid (dmards), on näidustatud ravi aktiivne psoriaatiline artriit (psa) täiskasvanud patsientidel, kellel on olnud ebapiisav reageerimine või kes on talumatus eelneva ravi dmard. psoriasisotezla on näidustatud ravi mõõduka kuni raske kroonilise psoriaas täiskasvanud patsientidel, kes ei vastanud või kellel on vastunäidustus või ei talu teiste süsteemne ravi, sealhulgas tsüklosporiin, metotreksaat või psoralen ja ultraviolett-valgus (puva).

Evropská unie - estonština - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Estonsko - estonština - Ravimiamet

chanelle pharmaceuticals manufacturing limited - fiproniil - täpilahus - 402mg 4.02ml 4.02ml 3tk; 402mg 4.02ml 4.02ml 8tk; 402mg 4.02ml 4.02ml 2tk; 402mg 4.02ml 4.02ml 4tk; 402mg 4.02ml 4.02ml 6tk; 402mg 4.02ml 4.02ml 24tk; 402mg 4.02ml 4.02ml 15tk; 402mg 4.02ml 4.02ml 60tk; 402mg 4.02ml 4.02ml 9tk; 402mg 4.02ml 4.02ml 150tk; 402mg 4.02ml 4.02ml 12tk; 402mg 4.02ml 4.02ml 20tk; 402mg 4.02ml 4.02ml 1tk

Estonsko - estonština - Ravimiamet

chanelle pharmaceuticals manufacturing limited - fiproniil - täpilahus - 50mg 0.5ml 0.5ml 24tk; 50mg 0.5ml 0.5ml 6tk; 50mg 0.5ml 0.5ml 4tk; 50mg 0.5ml 0.5ml 21tk; 50mg 0.5ml 0.5ml 1tk; 50mg 0.5ml 0.5ml 150tk; 50mg 0.5ml 0.5ml 90tk; 50mg 0.5ml 0.5ml 10tk; 50mg 0.5ml 0.5ml 12tk; 50mg 0.5ml 0.5ml 8tk; 50mg 0.5ml 0.5ml 20tk

Estonsko - estonština - Ravimiamet

chanelle pharmaceuticals manufacturing limited - fiproniil - täpilahus - 67mg 0.67ml 0.67ml 1tk; 67mg 0.67ml 0.67ml 2tk; 67mg 0.67ml 0.67ml 30tk; 67mg 0.67ml 0.67ml 18tk; 67mg 0.67ml 0.67ml 12tk; 67mg 0.67ml 0.67ml 3tk; 67mg 0.67ml 0.67ml 8tk; 67mg 0.67ml 0.67ml 21tk; 67mg 0.67ml 0.67ml 15tk; 67mg 0.67ml 0.67ml 60tk; 67mg 0.67ml 0.67ml 150tk; 67mg 0.67ml 0.67ml 9tk; 67mg 0.67ml 0.67ml 10tk; 67mg 0.67ml 0.67ml 24tk; 67mg 0.67ml 0.67ml 20tk

Estonsko - estonština - Ravimiamet

chanelle pharmaceuticals manufacturing limited - fiproniil - täpilahus - 268mg 2.68ml 2.68ml 8tk; 268mg 2.68ml 2.68ml 24tk; 268mg 2.68ml 2.68ml 30tk; 268mg 2.68ml 2.68ml 150tk; 268mg 2.68ml 2.68ml 2tk; 268mg 2.68ml 2.68ml 18tk; 268mg 2.68ml 2.68ml 21tk; 268mg 2.68ml 2.68ml 6tk; 268mg 2.68ml 2.68ml 20tk; 268mg 2.68ml 2.68ml 1tk; 268mg 2.68ml 2.68ml 90tk; 268mg 2.68ml 2.68ml 15tk; 268mg 2.68ml 2.68ml 10tk; 268mg 2.68ml 2.68ml 60tk; 268mg 2.68ml 2.68ml 3tk; 268mg 2.68ml 2.68ml 12tk